These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22499728)

  • 21. The sensitivity and specificity of markers for event times.
    Cai T; Pepe MS; Zheng Y; Lumley T; Jenny NS
    Biostatistics; 2006 Apr; 7(2):182-97. PubMed ID: 16079162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis.
    Djulbegovic B; Hozo I; Lyman GH
    MedGenMed; 2000 Jan; 2(1):E6. PubMed ID: 11104452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of the predictive value model in the analysis of test effectiveness.
    Galen RS
    Clin Lab Med; 1982 Dec; 2(4):685-99. PubMed ID: 7160151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
    Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple-marker screening for Down's syndrome: a method of assessing the statistical robustness of proposed tests.
    Morris JK; Bestwick J; Wald NJ
    J Med Screen; 2008; 15(2):55-61. PubMed ID: 18573771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The application of medical decision making to the mass screening: the basic principles on ROC analysis].
    Tsji I
    Rinsho Byori; 1990 May; 38(5):597-600. PubMed ID: 2199711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining predictors for classification using the area under the receiver operating characteristic curve.
    Pepe MS; Cai T; Longton G
    Biometrics; 2006 Mar; 62(1):221-9. PubMed ID: 16542249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.
    Steyerberg EW; Pencina MJ; Lingsma HF; Kattan MW; Vickers AJ; Van Calster B
    Eur J Clin Invest; 2012 Feb; 42(2):216-28. PubMed ID: 21726217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Receiver operating curve, an aid in decision making. Principles and applications illustrated with some examples].
    Vinatier D; Monnier JC
    J Gynecol Obstet Biol Reprod (Paris); 1988; 17(8):981-9. PubMed ID: 3069898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity and specificity can change in opposite directions when new predictive markers are added to risk models.
    Van Calster B; Steyerberg EW; D'Agostino RB; Pencina MJ
    Med Decis Making; 2014 May; 34(4):513-22. PubMed ID: 24378915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of diagnostic markers by goodness-of-fit tests.
    Nakas C; Yiannoutsos CT; Bosch RJ; Moyssiadis C
    Stat Med; 2003 Aug; 22(15):2503-13. PubMed ID: 12872305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of risk prediction models in cardiovascular disease research.
    Cui J
    Ann Epidemiol; 2009 Oct; 19(10):711-7. PubMed ID: 19628409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A principled approach to setting optimal diagnostic thresholds: where ROC and indifference curves meet.
    Irwin RJ; Irwin TC
    Eur J Intern Med; 2011 Jun; 22(3):230-4. PubMed ID: 21570638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).
    Chi YY; Zhou XH
    Stat Med; 2008 Jan; 27(2):182-4. PubMed ID: 17712782
    [No Abstract]   [Full Text] [Related]  

  • 35. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expected value of clinical information.
    Fuhrer R
    Bull Cancer; 1980; 67(4):405-11. PubMed ID: 7225599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing diagnostic tests on benefit-risk.
    Pennello G; Pantoja-Galicia N; Evans S
    J Biopharm Stat; 2016; 26(6):1083-1097. PubMed ID: 27548805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical utility curve: a proposal to improve the translation of information provided by prediction models to clinicians.
    Campbell DJ
    BMC Res Notes; 2016 Apr; 9():219. PubMed ID: 27080381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The summary test tradeoff: a new measure of the value of an additional risk prediction marker.
    Baker SG
    Stat Med; 2017 Dec; 36(28):4491-4494. PubMed ID: 29156500
    [No Abstract]   [Full Text] [Related]  

  • 40. A maximally selected test of symmetry about zero.
    Laska E; Meisner M; Wanderling J
    Stat Med; 2012 Nov; 31(26):3178-91. PubMed ID: 22729950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.